Advances in Hemophilia Treatment

New developments and therapies for the treatment for Hemophilia.

Breaking Ground in NASH Treatment: Resmetirom on the Horizon

Development in treatment for patients with non-alcoholic steatohepatitis (NASH).

Update on Regulatory Review of Gene Therapy for Duchenne Muscular Dystrophy

Patients and families with Duchenne Muscular Dystrophy (DMD) await regulatory action.

Spinal Cord Injuries: The Impacts, Current and Future Treatments

Looking at treatments with the potential to enhance outcomes for those suffering from spinal cord injuries.

FDA Approves First Gene Therapy for Rare Skin Disorder, Offering New Hope for Wound Healing in Dystrophic Epidermolysis Bullosa (DEB)

Vyjuvek™ (beremagene geperpavec), a topical gene therapy for the relief of a rare genetic skin disorder.

Pharmaceutical Companies Turn to AscellaHealth for Consultative Business Model, Including Robust Pre-Commercialization and Market Access Services

Specialty drug manufacturers are seeking innovative approaches to effectively launch new products.

Pursuing A New Paradigm in Inclusive Research

The significance of clinical trials to provide more robust data, ultimately leading to more effective medicines for patients who need them.

End-to-End Solutions Optimize Rare Disease Clinical Trials and Product Commercialization

Pharmaceutical manufacturers rely upon AscellaHealth as a single resource for managing all phases of rare disease clinical trials.

A Look at von Willebrand Disease

An inherited blood clotting disorder caused by either a deficiency or a dysfunction of the von Willebrand factor (vWf) protein.

Pursuing A New Paradigm in Inclusive Research

The significance of clinical trials to provide more robust data, ultimately leading to more effective medicines for patients who need them.

HUB & Patient Support Solutions Complement Pre-Commercialization Services

AscellaHealth’s expanded HUB/ Patient Support Services for Life Sciences manufacturers are recognized as the best-in-class outsourced solutions for successful medication access, compliance and persistency and enhanced outcomes.

Re-Think. Re-Consider. Re-Calibrate.

2023 Go-to-Market Strategies for Launching Specialty Drugs, Gene & Cell Therapies

Something for Everyone at Rare Disease Week on Capitol Hill

Rare Disease Week on Capitol Hill, February 28th through March 2nd, 2023.

AscellaHealth Specialty Pharmacy Distribution & Market Access Webinar Highlights

Experts provide in-depth insights on commercialization strategy, distribution models and demonstrating therapeutic value of Rare Disease & Gene/Cell therapies for patients, payers, and providers.

AscellaHealth Family of Companies Announces Founding Sponsorship: Gene Therapy and Specialty Pharmacy Awareness Month

September 2022: Join us in recognizing industry innovations

Global Genes: Improving the Path to Diagnosis and Treatment for Individuals Living with Rare Disease

With more than 10,000 rare diseases, Global Genes focuses on advancing innovation and overcoming challenges.

Patient-First Approach: Initial Step in Addressing Nation’s Health Inequities

Removing barriers to reach Health equity.

Changing the Face of Market Access and Commercialization

AscellaHealth Family of Companies brings integrated, customized approach for specialty drugs underscoring value of effective payer strategies.

Optimizing Treatment for Rare Genetic Condition: Cushing’s Syndrome

Cushing’s syndrome, a rare endocrine disorder and FDA approved treatments.

Update on Gene Therapy and Genome-Editing for Rare Diseases

There’s some upbeat news in gene therapy and genome-editing treatments.

Pharmaceutical Companies Turn to AscellaHealth Family of Companies for Consultative Business Model, Including Robust Pre-Commercialization and Market Access Services

Specialty drug manufacturers are seeking innovative approaches to effectively launch new products.

Patient Services and Hub Solutions for Life Sciences: Ensuring Specialty Product Access and Market Entry, Optimizing Outcomes for Rare Disease Patients

The rare disease community is gaining attention around the world, shining a light on the challenges and barriers to accessing care.

Optimizing Treatment for Rare Genetic Condition Hereditary Angioedema

Hereditary Angioedema (HAE) is a rare, unpredictable and potentially life-threatening genetic condition.

Foundation for the National Institutes of Health Accelerates Biomedical Research and Strategies Around the World

FNIH manages alliances with public and private institutions in support of the mission of the National Institutes of Health (NIH).

Medications for Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is the leading cause of severe vision loss in adults over age 60.